Shanghai Henlius Biotech Announces Regulatory Approval for Groundbreaking Gastric Cancer Treatment
Shanghai Henlius Biotech, Inc. (Stock code: 2696) has disclosed a major regulatory milestone that could significantly impact its business outlook and share price. The company announced that its new drug application (NDA) for an innovative indication of HANSIZHUANG (serplulimab injection) in combination with chemotherapy for perioperative (neo-/adjuvant) treatment of resectable gastric cancer has been officially approved by the National Medical Products Administration (NMPA) of China.
Key Highlights for Investors
- New Indication Approval: HANSIZHUANG, an anti-PD-1 monoclonal antibody developed by Henlius, is now approved for use with Oxaliplatin and S-1 for neoadjuvant treatment in patients with resectable gastric cancer whose tumors express PD-L1 (CPS ≥ 5), followed by adjuvant monotherapy after surgery.
- Clinical Evidence: The approval was based on a randomized, double-blind, multi-center Phase 3 clinical study. Results showed that HANSIZHUANG plus chemotherapy (followed by adjuvant HANSIZHUANG monotherapy) delivered statistically significant improvements in event-free survival (EFS) compared to the regimen of chemotherapy alone, meeting predefined efficacy criteria. Importantly, the regimen demonstrated superior safety and tolerability versus full-course chemotherapy.
- First Worldwide: This is the first ever approval globally for an immune monotherapy regimen to replace adjuvant chemotherapy in the perioperative setting for gastric cancer.
- Market Expansion: HANSIZHUANG is already approved for multiple indications in China and internationally, including lung cancer and esophageal cancer. It is also marketed across the EU, UK, Southeast Asia, India, and has received Orphan Drug Designation in the US, Switzerland, South Korea, among others.
- Pipeline Progress: Henlius continues to advance additional clinical studies for HANSIZHUANG and related combination therapies globally, including trials for various cancers (lung, head and neck, colorectal, etc.) and in multiple regions. Notable ongoing studies include bridging studies in the US and Japan, international multi-center trials in the US, Australia, EU, and Asia.
- Market Data: According to IQVIA MIDAS™, global sales of PD-1 targeting monoclonal antibody drugs are expected to reach approximately US\$50.871 billion in 2025, suggesting substantial commercial potential.
- Potential Impact: This approval is likely to enhance HANSIZHUANG’s market competitiveness, offer more treatment options for gastric cancer patients in mainland China, and potentially drive revenue growth given the unique position of the therapy.
Implications for Shareholders
- Share Price Sensitivity: The approval of a first-in-class therapy in a major cancer indication is a material event that could positively affect Henlius’s share value, given its potential to capture a significant share of the PD-1 monoclonal antibody market and differentiate itself from competitors.
- Competitive Advantage: The ability to replace adjuvant chemotherapy with immune monotherapy after surgery sets a new standard in perioperative gastric cancer care, strengthening Henlius’s portfolio and international reputation.
- Global Strategy: The company’s ongoing international clinical trials and marketing approvals position it for further expansion and partnerships.
Corporate Governance: The board of directors, chaired by Wenjie Zhang, continues to oversee Henlius’s strategic initiatives, with a mix of executive, non-executive, and independent directors ensuring robust governance practices.
Conclusion
The regulatory approval of HANSIZHUANG for perioperative gastric cancer treatment marks a transformative milestone for Shanghai Henlius Biotech, potentially catalyzing significant growth and solidifying its leadership in the immuno-oncology field. Investors should monitor subsequent commercialization, global expansion, and clinical developments closely, as these factors may have substantial impact on share performance.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult financial professionals before making investment decisions.
上海復宏漢霖生物技術有限公司公佈突破性胃癌治療方案獲批
上海復宏漢霖生物技術有限公司（股份代號：2696）近日公佈一項對公司前景和股價或有重大影響的里程碑事件。公司宣佈，其自主研發的創新型抗PD-1單克隆抗體漢斯狀（serplulimab注射液），聯合化療用於可切除胃癌（腫瘤PD-L1表達CPS≥5）新輔助及術後輔助治療的新適應症，已獲中國國家藥品監督管理局（NMPA）正式批准。
投資者重點摘要
- 新適應症獲批：漢斯狀聯合Oxaliplatin和S-1新輔助治療可切除胃癌，術後單藥輔助治療，適用於腫瘤PD-L1表達CPS≥5患者。
- 臨床證據：批准基於隨機、雙盲、多中心Ⅲ期臨床研究。結果顯示，漢斯狀聯合化療並術後單藥輔助顯著改善患者的無事件生存期（EFS），達到預設療效標準，且安全性和耐受性優於全程化療。
- 全球首創：這是全球首個免疫單藥替代化療的胃癌圍手術期治療方案獲批。
- 市場擴展：漢斯狀已於中國及全球多地（歐盟、英國、東南亞、印度等）獲批多個適應症，並獲美國、瑞士、韓國等地Orphan Drug Designation。
- 研發進展：公司正推進多項全球臨床研究，包括肺癌、頭頸癌、結直腸癌等，覆蓋美國、日本、澳洲、歐洲、亞洲等多國。
- 市場數據：據IQVIA MIDAS™數據，預計2025年全球PD-1單克隆抗體藥品銷售額約為508.71億美元，商業潛力巨大。
- 潛在影響：此批准將提升漢斯狀市場競爭力，為中國胃癌患者提供更多治療選擇，預期有助於公司收入增長和品牌提升。
股東需知
- 股價敏感性：全球首創療法獲批，對股份價值具有積極影響，市場份額及競爭優勢大幅提升。
- 競爭優勢：免疫單藥替代術後化療，開創胃癌新標準，鞏固公司產品線及國際地位。
- 全球戰略：國際臨床試驗及市場拓展，為公司增長及合作帶來更多機遇。
公司治理：董事會由張文杰先生擔任主席，組合包括執行董事、非執行董事及獨立董事，保障公司戰略和監管合規。
總結
漢斯狀圍手術期胃癌新適應症獲批，標誌公司在免疫腫瘤領域的重要突破。投資者應密切關注後續商業化、市場拓展及臨床進展，這些因素可能對股份表現產生重大影響。
免責聲明：本文僅供資訊參考，不構成任何投資建議。投資者須自行進行盡職調查及諮詢專業意見，方可作出投資決策。
